This was the stock's third consecutive day of losses.

Pfizer's Coming for AbbVie's Market Share. ... (now that Humira is seeing competition from generics as a result of going over the patent cliff in the U.S. this year).

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

AbbVie (ABBV-1.53%) and Pfizer (PFE-1.88%) stand out as two of the best in the industry. So far this year, Pfizer has been the bigger winner in terms of stock performance .

We compare AbbVie and Pfizer and determine which is a better high-yield pick for investors. Click here to know the results.

Pfizer’s stock has declined by 11% since early February after the WHO declared the coronavirus a global health emergency, while AbbVie’s stock has fared much better and gained 22%. The ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) rank as two of the largest and most successful drugmakers on the planet. The two companies are leaders in therapeutic areas including immunology and ...

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune disease treatment by resetting the immune system.

If you're looking for juicy dividend yields, you might want to check out big pharmaceutical stocks. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) stand out as two of the best in the industry.

Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High ...